Modality
Gene Therapy
MOA
SOS1i
Target
IL-23
Pathway
Neuroinflam
MDDGastric Ca
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
Nov 2020
→ Apr 2031
Phase 1Current
NCT04600093
2,155 pts·MDD
2020-11→2025-01·Recruiting
NCT07649708
516 pts·Gastric Ca
2023-09→2031-04·Not yet recruiting
2,671 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-261.2y agoPh2 Data· MDD
2031-04-215.1y awayPh2 Data· Gastric Ca
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Recruit…
P1/2
Not yet…
Catalysts
Ph2 Data
2025-01-26 · 1.2y ago
MDD
Ph2 Data
2031-04-21 · 5.1y away
Gastric Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04600093 | Phase 1/2 | MDD | Recruiting | 2155 | OS |
| NCT07649708 | Phase 1/2 | Gastric Ca | Not yet recr... | 516 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Tezecilimab | Regeneron | Approved | IL-23 |